Search

Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment

Volunteering to Strengthen the Human-Animal Bond

Cardio-Renal-Metabolic diseases

Boehringer Ingelheim Launches Groundbreaking Initiative “Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes

Jardiance® (empagliflozin) Granted Designation for Heart Failure | Boehringer Ingelheim US

The FDA granted Breakthrough Therapy designation for JARDIANCE® (empagliflozin) as treatment for HFpEF. View ISI, PI and Med Guide.

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction

Boehringer Ingelheim and Junior Achievement: A decade of inspiring futures

Boehringer Ingelheim celebrates its decade-long partnership and volunteering milestone.

New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US

The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.

Employees compassionately help local communities with country-wide food drive

Coming together to bring food to people in need

Championing minds for generations both in and out of the workplace

Boehringer Ingelheim is now certified for Mental Health America’s (MHA) Bell Seal for Workplace Mental Health.

Data Shows Jardiance® (empagliflozin) Cardiorenal Risk Reductions | Boehringer Ingelheim US

The EMPA-REG OUTCOME® trial shows JARDIANCE reduces CV and renal risk in adults with T2D & known CV disease. View ISI, PI & Med Guide.

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.

Promising Phase II Results in Chronic Kidney Disease

Boehringer Ingelheim announced promising Phase II data for people with chronic kidney disease

Boehringer welcomes 2023 Gold Report

Boehringer welcomes 2023 GOLD Report Positioning LAMA/LABA as preferred treatment

Full results from EMPERIAL exercise ability trials presented

Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes

Expanded Access Programs

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.

U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes

First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US

Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies

Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers